Ocugen announce Phase 3 enrolment completion for OCU400, the largest gene agnostic therapy trial for RP
Biotechnology company Ocugen has announced the enrolment completion of their phase 3 clinical trial for OCU400.
Search results
Biotechnology company Ocugen has announced the enrolment completion of their phase 3 clinical trial for OCU400.
Join our as our young adults share their lived experiences of navigating inherited sight loss.
The latest webinar from Retina UK.
VeonGen has reported encouraging early results from a clinical trial of VG801, an investigational gene therapy for Startgardt disease, a genetic retinal condition that currently has no approved treatments.
Gabriel Velichkova is in the second year of her Retina UK and Macular Society joint-funded PhD project at University College London (UCL) Institute of Ophthalmology.
Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.
Hajrah Sarkar is a PhD student whose project is funded by Retina UK.
The project aims to develop a cost effective method of examining the entire ABCA4 gene to look for variations that might cause disease.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.